- Poster presentation
- Open Access
Methotrexate shows the same efficacy and safety in the real world in all subtypes of JIA as in the controlled trial
© Foedvari and Wierk; licensee BioMed Central Ltd. 2008
- Published: 15 September 2008
- Public Health
- Adverse Effect
- Retrospective Study
Methotrexate (MTX) is the mostly used second line agent to treat Juvenile idiopathic arthritis (JIA). This study presents a retrospective data evaluation.
To prove the efficacy and safety of MTX in all subtypes of JIA in a retrospective cohort.
Single center open-label evaluation of the efficacy and safety of MTX treatment in patients with JIA where treatment was initiated between 31 st of March 2005 and 31 st of December 2007.
105 patients were MTX initiated aged between 1 to 17 years. 61 of them were female (58.1%). The mean treatment duration was 13.9 months. The mean MTX dose was 14.7 mg/m2/week. The response to therapy is shown in table 1, response occurred at months 3 and stayed stable over the observation period.
At 3 months
At 6 months
At 12 months
Number of swollen joints
Number of tender joints
Number of joints with LROM
Physician global (VAS)
Elevated Sedimentation rate
Adverse effects (AE) were reported by 41% of the patients, which were evenly distributed over the observation period. One severe AE occurred, one patient died with ALL.
In this real world retrospective study of all JIA subsets MTX appears to be a safe and effective drug.
This article is published under license to BioMed Central Ltd.